Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

CURATIVE CamoUflaged nanopaRticle-driven duAl Therapy to eradicate aggressIVe nEuroblastoma

Coordinator
Universidad De Navarra, Spain
Runs
1 June 2026 to 31 May 2028
Status
Running
EU funding
€194k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101207818

What the project is doing

In the project's own words, from its summary on CORDIS.

Neuroblastoma (NB) is a highly aggressive paediatric cancer, accounting for 15% of childhood cancer deaths. The 5-year survival rate for high-risk NB patients is less than 50%. Despite the significant advances in treatment options, the high tumour heterogeneity, drug resistance, and severe toxicities associated with conventional therapies continue to result in poor outcomes for high-risk NB patients. Recent studies showed that these challenges, along with frequent relapses, may be linked to the intrinsic resistance of a specific population of cells known as cancer stem cells (CSCs).

CURATIVE aims to address this by developing a chitosan-based nanoparticle (NP) that co-encapsulates a systematically identified and optimized synergistic combination of drugs designed to target both CSCs and a key mechanism driving NB progression. The NP, which will enable controlled and sustained drug release, will be coated with plasma membranes derived from NB cells to enhance tumour targeting and accumulation through homotypic targeting.

By leveraging the innovative use of NB cell membranes, the NP can closely mimic the tumour environment, allowing it to evade the immune system and preferentially accumulate at the tumour site. This approach enhances both specificity and efficacy, while simultaneously reducing off-target effects and minimizing systemic toxicity. The expected outcomes of CURATIVE include increased survival and treatment efficacy, reduced relapse rates and toxicity, and improved quality of life for paediatric patients.

Overall, CURATIVE is positioned to provide valuable insights and resources to the scientific community, supporting the EU's objectives of advancing innovation in paediatric cancer care.

Topics

Who is involved

OrganisationCityCountryRole
Universidad De NavarraPamplonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI